Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.
CITATION STYLE
Kastenhuber, E. R., Craig, J., Ramsey, J., Sullivan, K., Sage, J., de Oliveira, S., … Abou-Alfa, G. K. (2019). Road map for fibrolamellar carcinoma: progress and goals of a diversified approach. Journal of Hepatocellular Carcinoma, Volume 6, 41–48. https://doi.org/10.2147/jhc.s194764
Mendeley helps you to discover research relevant for your work.